Primary outcome measures included enteral intake at 2 weeks and days to reach 120 ml kg−1 per day of enteral feedings.,Primary outcome measures included enteral intake 2 weeks days reach 120 kg−1 day enteral feedings.,C0205225|C1274040|C0079809|C0332257|C1304890|C1512806|G0000000|C0439230|C0439228|C2584321|C1442061|G0000000|C0332173|C1304890|C0204695
"There was no statistically significant difference in progression-free survival (time from randomisation until first evidence of progression after chemotherapy, 10.2 vs 10.8 months; hazard ratio, 1.08; 95% CI 0.71–1.64; P=0.73).","There statistically difference progression-free survival (time randomisation evidence progression chemotherapy, 10.2 10.8 months; hazard ratio, 1.08; 95% CI 0.71–1.64; P=0.73).",G0000000|C0038215|C1705241|C0242656|C0038952|C0040223|C0034656|C3887511|C0242656|C0013216|C0450371|C0450371|C0439231|C0598697|C0456603|C0450371|C0450371|C0008107|G0000000|C0369773
"The impact of our intervention on female condom knowledge, attitudes, and self-efficacy was assessed using psychosocial scales.","The impact intervention female condom knowledge, attitudes, self-efficacy assessed psychosocial scales.",G0000000|C1825598|C0886296|C0015780|C0009653|C0376554|C0004271|C0600564|C1516048|C0542298|C0175659
RESULTS—There were no significant differences between the two groups in the numbers of electroretinograms performed at 36 weeks of postmenstrual age.,RESULTS—There differences electroretinograms performed 36 weeks postmenstrual age.,G0000000|C1705241|C0013867|C0884358|C0450371|C0439230|G0000000|C0001779
"(6) Penetration of SDM in MDTMs as measured by an adapted version of the Metric for the Observation of Decision Making in Multidisciplinary Team Meetings (MDT-MODe, [69]).","(6) Penetration SDM MDTMs measured adapted version Metric Observation Decision Making Multidisciplinary Team Meetings (MDT-MODe, [69]).",G0000000|C0205321|C0643808|G0000000|C0444706|C2937289|C0333052|C0699680|C0302523|C0679006|C1881534|C0242479|C0871489|C0556656|C3896649|C0450371
"However, GEM monotherapy significantly improved OS compared with S-1 treatment.","However, GEM monotherapy improved OS compared S-1 treatment.",G0000000|G0000000|G0000000|C0184511|C0229090|C1707455|G0000000|C0039798
The main outcome variable was presence of an abdominal wound dehiscence or burst.,The main outcome variable presence abdominal wound dehiscence burst.,G0000000|C0205225|C1274040|C0439828|C0150312|C0000726|C0043250|C0149663|C0439818
Week 5 median (CV%) plasma SN-38 Cmax values were lower in Arm A than Arm B (22.4 ng ml−1 (61.5%) vs 31.6 ng ml−1 (62.3%)).,Week 5 median (CV%) plasma SN-38 Cmax values lower Arm A Arm B (22.4 ng ml−1 (61.5%) 31.6 ng ml−1 (62.3%)).,C0332174|G0000000|C0549183|C3538987|C0032105|C0037173|C2347813|C0042295|C0441994|C0446516|G0000000|C0446516|G0000000|G0000000|C0450371|G0000000|C0450371
"SF-36 subscales that demonstrated significant improvements included physical functioning (Ptrend<0.001), role-physical (Ptrend=0.035), general health (Ptrend=0.011), and vitality (Ptrend=0.025; Supplementary Table 1).","SF-36 subscales demonstrated improvements included physical functioning (Ptrend<0.001), role-physical (Ptrend=0.035), health (Ptrend=0.011), vitality (Ptrend=0.025; Supplementary Table 1).",C0037712|G0000000|G0000000|C2986411|C0332257|C0031809|C0205245|C1442061|C0035820|C1442061|C0018684|C1442061|C0424589|C1442061|G0000000|C0039224|G0000000
The primary endpoint is the rate of PDS response at 3 days after surgery.,The primary endpoint rate PDS response 3 days surgery.,G0000000|C0205225|C2349179|C0871208|G0000000|C0871261|G0000000|C0439228|C0038894
"The primary outcome is adoption of SDM, measured by the 9-item Shared Decision Making Questionnaire.","The primary outcome adoption SDM, measured 9-item Shared Decision Making Questionnaire.",G0000000|C0205225|C1274040|C0001593|C0643808|C0444706|C1551338|C0237876|C0679006|C1881534|C0034394
"In conclusion, one year 5FU plus levamisole was of benefit in stage II and III colonic cancer; in rectal cancer a significant positive effect could not be demonstrated.","In conclusion, 5FU levamisole benefit stage II III colonic cancer; rectal cancer positive demonstrated.",G0000000|C1707478|G0000000|C0023556|C0814225|C0205390|G0000000|C0439070|C0009368|C0006826|C0205052|C0006826|C0439178|G0000000
"Secondary endpoints included hemoglobin (Hb) on admission, Hb difference from randomization to admission, ICU admission, perioperative morbidity (defined as new onset infection, respiratory failure, renal impairment, deep venous thrombosis), discharge Hb, length of stay, Hb at follow-up, Hb difference from discharge to follow-up, iron status, 30-day mortality, and quality of life (QoL).","Secondary endpoints included hemoglobin (Hb) admission, Hb difference randomization admission, ICU admission, perioperative morbidity (defined onset infection, respiratory failure, renal impairment, deep venous thrombosis), discharge Hb, length stay, Hb follow-up, Hb difference discharge follow-up, iron status, 30-day mortality, quality life (QoL).",C0027627|C2349179|C0332257|C0019046|C0019046|C0184666|C0019046|C1705241|C0034656|C0184666|C0021708|C0184666|C1518988|C0026538|C1704788|C0206132|C0009450|C0521346|C0231174|C0022646|C0221099|C0205125|C0042449|C0040053|C0012621|C0019046|C1444754|G0000000|C0019046|C0589120|C0019046|C1705241|C0012621|C0589120|C0302583|C0449438|C0450371|C0026565|C0332306|C0376558|C0518214
The original primary endpoint was PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) via IRF in the ITT population.,The original primary endpoint PFS Response Evaluation Criteria Solid Tumors version 1.1 (RECIST v1.1) IRF ITT population.,G0000000|C0205313|C0205225|C2349179|C0242792|C0871261|C0220825|C0243161|C0205208|C0027651|C0333052|G0000000|C1709926|C0078433|C1446165|G0000000|C0032659
"Efficacy endpoints were incidence and severity of radiation-induced diarrhea, number of patients who discontinued radiotherapy because of diarrhea, daily number of bowel movements, and the time from the start of the study to the use of loperamide as rescue medication for diarrhea.","Efficacy endpoints incidence severity radiation-induced diarrhea, patients discontinued radiotherapy diarrhea, daily bowel movements, time start study loperamide rescue medication diarrhea.",C1280519|C2349179|C0021149|C0439793|C0034519|C0011991|C0030705|C1444662|C0034619|C0011991|C0332173|C0021853|C0026649|C0040223|C0439659|C0557651|C0023992|G0000000|C0013227|C0011991
"The primary outcome weight gain as g/kg/day was estimated from the linear mixed model for weight estimates, including adjustment over the duration of the trial (56 days) and the difference between the two RUTFs.","The primary outcome weight gain g/kg/day estimated linear mixed model weight estimates, including adjustment duration trial (56 days) difference RUTFs.",G0000000|C0205225|C1274040|C0005910|C1517378|C1532536|C0750572|C0205132|C0205430|C3161035|C0005910|C0750572|C0332257|C0376209|C0449238|C0008976|C0450371|C0439228|C1705241|G0000000
"Our results showed that the intercalated addition of gefitinib did not improve the treatment outcomes not only with regard to NPR but also with regard to ORR, PFS, or OS.","Our intercalated addition gefitinib improve treatment outcomes regard NPR regard ORR, PFS, OS.",G0000000|G0000000|C0332287|C1122962|G0000000|C0039798|C1274040|G0000000|C1417814|G0000000|G0000000|C0242792|C0229090
"Secondary outcomes were referral to radiography and rate of recovery at the follow-up consultation after 2 weeks with the following five alternatives: “fully recovered”, “almost recovered”, “slightly improved”, “unchanged”, and “worse”.","Secondary outcomes referral radiography rate recovery follow-up consultation 2 weeks alternatives: “fully recovered”, “almost recovered”, “slightly improved”, “unchanged”, “worse”.",C0027627|C1274040|C0034927|C0034571|C0871208|C0237820|C0589120|C0009818|G0000000|C0439230|C1523987|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
"At T1 there was a significant difference on anxiety (p<.0001), with the INT group having lower mean scores (less anxiety) than the UMC group.","At T1 difference anxiety (p<.0001), INT lower scores (less anxiety) UMC group.",G0000000|C0041403|C1705241|C0003467|C0369773|C0063789|C0441994|C0449820|C0439092|C0003467|G0000000|C0441833
The primary endpoint was clinically relevant postoperative pancreatic fistula.,The primary endpoint clinically relevant postoperative pancreatic fistula.,G0000000|C0205225|C2349179|G0000000|C2347946|C0032790|C0030274|C0016169
"The secondary end points were OS, overall response rate (ORR), time-to-treatment failure (TTF), and safety.","The secondary OS, response rate (ORR), time-to-treatment failure (TTF), safety.",G0000000|C0027627|C0229090|C0871261|C0871208|G0000000|C3494202|C0231174|C1332112|C0036043
"We focus here on updating findings for the primary endpoint (incidence of invasive breast cancer) and for all key secondary endpoints, including noninvasive breast cancer, endometrial and other cancers, and vascular-related events.","We focus updating findings primary endpoint (incidence invasive breast cancer) key secondary endpoints, including noninvasive breast cancer, endometrial cancers, vascular-related events.",G0000000|C0205234|C1519814|C2607943|C0205225|C2349179|C0021149|C0205281|C0006141|C0006826|G0000000|C0027627|C2349179|C0332257|C0205303|C0006141|C0006826|C0227843|C0006826|C1266852|C0441471
The primary outcome is observed SDM in decision-making consultations.,The primary outcome observed SDM decision-making consultations.,G0000000|C0205225|C1274040|C1441672|C0643808|C0011109|C0009818
"Baseline measures also included the Hot Flash Related Daily Interference Scale (HFRDIS),2 Center for Epidemiologic Studies Depression Scale (CES-D),10 Hospital Anxiety and Depression Scale-Anxiety Subscale (HADS-A),11 and Medical Outcomes Study Sleep Scale (MOS-Sleep Scale).12","Baseline measures included Hot Flash Related Daily Interference Scale (HFRDIS),2 Center Epidemiologic Studies Depression Scale (CES-D),10 Hospital Anxiety Depression Scale-Anxiety Subscale (HADS-A),11 Medical Outcomes Study Sleep Scale (MOS-Sleep Scale).12",C0168634|C0079809|C0332257|C0444519|C0181637|C0439849|C0332173|C0521102|C0175659|C3641714|C0205099|C0014507|C0947630|C0011570|C0175659|C2699160|C0019994|C0003467|C0011570|C0175659|G0000000|C0048008|C0199168|C1274040|C0557651|C0037313|C0175659|C3813178|C0175659
"OS = overall survival, PFS = progression free survival, ITT = intend-to-treat.","OS = overall survival, PFS = progression free survival, ITT = intend-to-treat.",G0000000|C0038952|G0000000|C0332296|C0038952|G0000000
"Moreover, there was a clear trend for azithromycin to increase the time to the first exacerbation compared to placebo.","Moreover, trend azithromycin increase time exacerbation compared placebo.",G0000000|C1521798|C0052796|C0442805|C0040223|G0000000|C1707455|C0032042
"The five primary outcomes were auditory comprehension and expressive language scores, phonology error rate, the score for the Bristol language development scales, and a binary variable indicating whether the child, by 12 months, had improved sufficiently on the single clinical measure on which he or she had entered the study to no longer satisfy that particular criterion.","The primary outcomes auditory comprehension expressive language scores, phonology error rate, score Bristol language development scales, binary variable indicating child, 12 months, improved single clinical measure entered study satisfy criterion.",G0000000|C0205225|C1274040|C0439825|C0162340|C0185117|C0023008|C0449820|C0597725|C0743559|C0871208|C0449820|G0000000|C0023008|C0243107|C0175659|C1706942|C0439828|G0000000|C0008059|C0450371|C0439231|C0184511|C0037179|C0205210|C0079809|C1521975|C0557651|G0000000|C0243161
"Training efficacy is assessed in the context of an encounter with a simulated advanced stage cancer patient at baseline and after the CST for the experimental group, and after four months for the waiting-list group.","Training efficacy assessed context encounter simulated advanced stage cancer patient baseline CST experimental group, months waiting-list group.",C0040607|C1280519|C1516048|C0449255|C0545082|C0284447|C0205179|C0205390|C0006826|C0030705|C0168634|C3539520|C1517586|C0441833|C0439231|C0043010|C0441833
"We also measured time spent in the emergency department, use of adrenaline (epinephrine), and the duration of subsequent croup and viral symptoms as secondary outcome measures.","We measured time spent emergency department, adrenaline (epinephrine), duration subsequent croup viral symptoms secondary outcome measures.",G0000000|C0444706|C0040223|C0680968|C0013956|C1704729|C0014563|C0014563|C0449238|C0332282|C0010380|C0521026|C0683368|C0027627|C1274040|C0079809
Mean difference pre-to-post treatment in secondary outcome measures within each treatment group.,Mean difference pre-to-post treatment secondary outcome measures treatment group.,C0444504|C1705241|C0332152|C0039798|C0027627|C1274040|C0079809|C0039798|C0441833
"Outcome measures were death, loss to follow-up (LTFU) and virological suppression (VS).","Outcome measures death, loss follow-up (LTFU) virological suppression (VS).",C1274040|C0079809|C0011065|C1517945|C0589120|G0000000|C0205466|C0221103|G0000000
"Secondary outcomes included overall survival, progression-free survival, time to treatment failure, and safety.","Secondary outcomes included survival, progression-free survival, time treatment failure, safety.",C0027627|C1274040|C0332257|C0038952|C0242656|C0038952|C0040223|C0039798|C0231174|C0036043
"We found no significant differences between postsurgical colon cancer patients undergoing either GP-led or surgeon-led follow-up for our primary outcome measures of quality of life, depression and anxiety and patient satisfaction.","We differences postsurgical colon cancer patients undergoing GP-led surgeon-led follow-up primary outcome measures quality life, depression anxiety patient satisfaction.",G0000000|C1705241|G0000000|C0009368|C0006826|C0030705|G0000000|C3811116|C0582175|C0589120|C0205225|C1274040|C0079809|C0332306|C0376558|C0011570|C0003467|C0030705|C0242428
Frequency of exclusive breastfeeding until 6 months was significantly higher in the loss-framed group (P = 0.03).,Frequency exclusive breastfeeding 6 months loss-framed (P = 0.03).,C0376249|C1548966|C0006147|G0000000|C1517945|G0000000
"Length of hospital stay, time to start walking with aids, time to start independent walking, time absent from school, parent satisfaction, and range of knee motion were compared between the two groups 6 months after injury.","Length hospital stay, time start walking aids, time start independent walking, time absent school, parent satisfaction, range knee motion compared 6 months injury.",C1444754|C0019994|G0000000|C0040223|C0439659|C0080331|C0001175|C0040223|C0439659|C0085862|C0080331|C0040223|C0332197|C0036375|C0030551|C0242428|C1514721|C0022742|C0026597|C1707455|G0000000|C0439231|C3263722
"Additionally, there were no significant differences by randomization in maternal RBC DHA levels assessed at 26 weeks gestation (p = 0.79), however, there were significant differences in RBC DHA levels at 36 weeks gestation (p < 0.001) between the placebo and the DHA-supplemented group.","Additionally, differences randomization maternal RBC DHA levels assessed 26 weeks gestation (p = 0.79), however, differences RBC DHA levels 36 weeks gestation (p < 0.001) placebo DHA-supplemented group.",G0000000|C1705241|C0034656|C2347083|C0014792|C0142831|C0441889|C1516048|C0450371|C0439230|C0032961|C0369773|G0000000|C0450371|G0000000|C1705241|C0014792|C0142831|C0441889|C0450371|C0439230|C0032961|C0369773|G0000000|C1442061|C0032042|C0142831|C0441833
We observed no associations between use of any individual supplement or multivitamin supplements and pancreatic cancer.,We observed associations individual supplement multivitamin supplements pancreatic cancer.,G0000000|C1441672|C0004083|C0027361|C0242295|C0301532|C0242295|C0030274|C0006826
"The secondary endpoints included the investigator‐assessed ORR, CR rate, PR rate, duration of response, time to response, PFS, OS, disappearance rate of B symptoms, median time to disappearance of B symptoms, occurrence rate of B symptoms, rate of change in the sum of the products of the greatest diameters of the target lesion, and the maximum rate of change in the sum of the products of the greatest diameters of the target lesion.","The secondary endpoints included investigator‐assessed ORR, CR rate, PR rate, duration response, time response, PFS, OS, disappearance rate B symptoms, median time disappearance B symptoms, occurrence rate B symptoms, rate change sum products diameters target lesion, maximum rate change sum products diameters target lesion.",G0000000|C0027627|C2349179|C0332257|G0000000|G0000000|C0201975|C0871208|C0279759|C0871208|C0449238|C0871261|C0040223|C0871261|C0242792|C0229090|G0000000|C0871208|G0000000|C0683368|C0549183|C0040223|G0000000|G0000000|C0683368|C0243132|C0871208|G0000000|C0683368|C0871208|C0392747|C1515051|C1514468|C1301886|C1521840|C0221198|C0806909|C0871208|C0392747|C1515051|C1514468|C1301886|C1521840|C0221198
The present findings indicate that the frequency of grade 3 or 4 diarrhoea may be reduced with the use of Lactobacillus supplementation.,The findings frequency grade 3 4 diarrhoea reduced Lactobacillus supplementation.,G0000000|C2607943|C0376249|C0441800|G0000000|G0000000|C0011991|C0392756|C0022938|C0242297
"Secondary end points were frequency of intracranial relapse at initially treated and at new sites, progression-free and overall survival, late toxicities, and quality of life.","Secondary frequency intracranial relapse initially treated sites, progression-free survival, late toxicities, quality life.",C0027627|C0376249|C0524466|C0035020|C0205265|C1522326|C0205145|C0242656|C0038952|C0205087|C0600688|C0332306|C0376558
Clinical response at the test of cure (TOC) or early termination (ET) visit was the primary efficacy endpoint of the study.,Clinical response test cure (TOC) termination (ET) visit primary efficacy endpoint study.,C0205210|C0871261|C0022885|C1880198|C1835664|C1549081|G0000000|C0545082|C0205225|C1280519|C2349179|C0557651
Current international recommendations favor higher amino acid intakes and fish oil–containing lipid emulsions.,Current international recommendations favor amino acid intakes fish oil–containing lipid emulsions.,C0521116|C1512888|C0034866|C0309049|G0000000|C0001128|C1512806|C0016163|G0000000|C0023779|C0014020
"Hemoglobin concentration is measured using the point-of-care HemoCue Hb 301 hemoglobinometer (HemoCue, Angelholm, Sweden) in all infants at 18 months of age (primary endpoint).","Hemoglobin concentration measured point-of-care HemoCue Hb 301 hemoglobinometer (HemoCue, Angelholm, Sweden) infants 18 months age (primary endpoint).",C0019046|C0004268|C0444706|C0282664|G0000000|C0019046|C1442061|C0181183|G0000000|G0000000|C0038995|C0021270|C0450371|C0439231|C0001779|C0205225|C2349179
The primary outcome is patient-reported quality of life.,The primary outcome patient-reported quality life.,G0000000|C0205225|C1274040|C0747307|C0332306|C0376558
The current report presents the clinical results of the THROMBOTECT study with respect to the incidence of symptomatic thromboembolism and hemorrhage as primary efficacy and safety outcomes as well as the secondary safety outcome of leukemia-related survival.,The current report clinical THROMBOTECT study respect incidence symptomatic thromboembolism hemorrhage primary efficacy safety outcomes secondary safety outcome leukemia-related survival.,G0000000|C0521116|C0684224|C0205210|G0000000|C0557651|C0679133|C0021149|C0231220|C0040038|C0019080|C0205225|C1280519|C0036043|C1274040|C0027627|C0036043|C1274040|C0023418|C0038952
"In a cross-sectional study conducted in Shanghai, China, we found men homozygous for low-activity associated catechol-O-methyltransferase (COMT) genotype to have a statistically significant 44 % lower urinary level of total tea polyphenols relative to men homozygous for high-activity COMT genotype [34].","In cross-sectional study conducted Shanghai, China, homozygous low-activity catechol-O-methyltransferase (COMT) genotype statistically 44 % lower urinary level total tea polyphenols relative homozygous high-activity COMT genotype [34].",G0000000|C0552389|C0557651|C0004927|G0000000|C0008115|C0019904|C0205251|C0007407|G0000000|C0017431|C0038215|C0450371|G0000000|C0441994|C0042027|C0441889|C0439175|C0039400|C0071649|C0080103|C0019904|C0205250|G0000000|C0017431|C0450371
We found no significant difference in length of stay between the groups.,We difference length stay groups.,G0000000|C1705241|C1444754|G0000000|C0441833
"The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range.","The primary study rate ovarian failure 2 years, ovarian failure defined absence menses preceding 6 months levels follicle-stimulating hormone (FSH) postmenopausal range.",G0000000|C0205225|C0557651|C0871208|C0205065|C0231174|G0000000|C0439234|C0205065|C0231174|C1704788|C0332197|C0025344|C0332152|G0000000|C0439231|C0441889|C0018120|C0019932|G0000000|C0232970|C1514721
"Our primary aim of testing the effect of the exercise program on patient-reported fatigue was not statistically significant, but the change in fatigue (−5.95) for the intervention group achieved a minimally important difference that is considered clinically relevant.","Our primary aim testing exercise program patient-reported fatigue statistically significant, change fatigue (−5.95) intervention achieved minimally difference considered clinically relevant.",G0000000|C0205225|C1947946|C0039593|C0015259|C1709697|C0747307|C0015672|C0038215|C0237881|C0392747|C0015672|G0000000|C0886296|G0000000|G0000000|C1705241|C0750591|G0000000|C2347946
"In this study, we showed that progressive renal injury in WT survivors with SFK occurs in a similar manner to that in children with SFK of non-oncological causes, even though the frequency may be lower.","In study, progressive renal injury WT survivors SFK occurs manner children SFK non-oncological causes, frequency lower.",G0000000|C0557651|C0205329|C0022646|C3263722|C2700323|C0206194|G0000000|C1709305|G0000000|C0008059|G0000000|C1518422|C0015127|C0376249|C0441994
"Secondary outcomes were uptake of 2 other adolescent vaccines, the meningococcal conjugate vaccine (MenACWY) and the tetanus-diphtheria-acellular pertussis vaccine (Tdap).","Secondary outcomes uptake 2 adolescent vaccines, meningococcal conjugate vaccine (MenACWY) tetanus-diphtheria-acellular pertussis vaccine (Tdap).",C0027627|C1274040|C0243144|G0000000|C0205653|C0042210|C0127526|C0301869|C0042210|C2003457|C0039614|C0043167|C0042210|G0000000
The primary outcome was spontaneous preterm birth at less than 37 and less than 34 weeks gestation.,The primary outcome spontaneous preterm birth 37 34 weeks gestation.,G0000000|C0205225|C1274040|C0205359|C0151526|C0005615|C0450371|C0450371|C0439230|C0032961
The secondary outcome also included comparison of number of patients classified as relapse and reinfection by the three methods to find out the concordance between the methods used and the genetic diversity observed based on PCR sequencing method.,The secondary outcome included comparison patients classified relapse reinfection methods concordance methods genetic diversity observed based PCR sequencing method.,G0000000|C0027627|C1274040|C0332257|C1707455|C0030705|C0008902|C0035020|C0205339|C0025663|C0680240|C0025663|C0017296|C1880371|C1441672|C1527178|C0032520|C1294197|C0025663
The primary endpoint was time to progression (TTP).,The primary endpoint time progression (TTP).,G0000000|C0205225|C2349179|C0040223|C0242656|C0084795
"Primary outcomes were (1) having ever obtained a Pap test and (2) being up-to-date for Pap tests, defined as having obtained a first test or having obtained a test after a lapse of more than 1 year.","Primary outcomes (1) Pap test (2) up-to-date Pap tests, defined test test lapse 1 year.",C0205225|C1274040|G0000000|C1740167|C0022885|G0000000|C0547043|C1740167|C0022885|C1704788|C0022885|C0022885|G0000000|G0000000|C0439234
"Symptom severity was measured during each interview observation by asking patients to rate the severity of each symptom on a scale of 0 (not present) to 10 (as severe as it possibly could be) and then summing severity ratings for each symptom, with higher scores indicating higher levels of severity (possible range = 0-120).","Symptom severity measured interview observation patients rate severity symptom scale 0 (not present) 10 (as severe be) summing severity ratings symptom, scores indicating levels severity (possible range = 0-120).",C1457887|C0439793|C0444706|C0021822|C0302523|C0030705|C0871208|C0439793|C1457887|C0175659|G0000000|C1518422|C0150312|C0450371|G0000000|C0205082|G0000000|C1515051|C0439793|C0871208|C1457887|C0449820|G0000000|C0441889|C0439793|C0332149|C1514721|G0000000|C1442061
"The secondary objectives are to assess the following: (1) the efficacy of EPC in terms of 1-year OS (intent-to-treat and per protocol analyses) and OS curves (per protocol analysis), (2) the patient-reported outcomes (quality of life, depression and anxiety) and the time until definitive deterioration (TUDD) for quality of life, (3) the number of patients receiving chemotherapy in their last 30 days of life, (4) the actual description of the PC package and (5) the presence or absence of advanced directives in patient files.","The secondary objectives assess following: (1) efficacy EPC terms 1-year OS (intent-to-treat protocol analyses) OS curves (per protocol analysis), (2) patient-reported outcomes (quality life, depression anxiety) time definitive deterioration (TUDD) quality life, (3) patients receiving chemotherapy 30 days life, (4) actual description PC package (5) presence absence advanced directives patient files.",G0000000|C0027627|C0018017|C1516048|C0231290|G0000000|C1280519|C0169014|C0233324|C0439234|C0229090|C0162425|C0442711|C0002778|C0229090|C0205134|G0000000|C0442711|C0002778|G0000000|C0747307|C1274040|C0332306|C0376558|C0011570|C0003467|C0040223|C0443196|C0868945|G0000000|C0332306|C0376558|G0000000|C0030705|C1514756|C0013216|C0450371|C0439228|C0376558|G0000000|C0237400|C0678257|C0031995|C0013194|G0000000|C0150312|C0332197|C0205179|C3871158|C0030705|C0016094
"Patient outcomes (creatinine/blood urea nitrogen, infection, acute/chronic rejection, graft loss, death) and cost effectiveness are to be examined.","Patient outcomes (creatinine/blood urea nitrogen, infection, acute/chronic rejection, graft loss, death) cost effectiveness examined.",C0030705|C1274040|C0201975|C0041942|C0028158|C0009450|C0439588|C0035015|C0181074|C1517945|C0011065|C0010186|C1280519|C0332128
"Daily treatment with 200 mgs EGCG administered three times a day (total 600 mg/d) for one year significantly reduced progression to prostate cancer in men in the treatment arm (incidence, approximately 3%), compared to men on placebo (incidence, 30%) [44].","Daily treatment 200 mgs EGCG administered times day (total 600 mg/d) reduced progression prostate cancer treatment arm (incidence, 3%), compared placebo (incidence, 30%) [44].",C0332173|C0039798|C1442061|C0024467|C0059438|C1521801|C0040223|C0332173|C0439175|C1442061|C0439422|C0392756|C0242656|C0033572|C0006826|C0039798|C0446516|C0021149|G0000000|C1707455|C0032042|C0021149|C0450371|C0450371
No significant difference was found between the PEI and PAI groups.,No difference PEI PAI groups.,G0000000|C1705241|C0814202|C1620101|C0441833
Primary outcomes were nonadipose mass for the amino acid intervention and IHCL for the lipid intervention.,Primary outcomes nonadipose mass amino acid intervention IHCL lipid intervention.,C0205225|C1274040|G0000000|C0577559|G0000000|C0001128|C0886296|G0000000|C0023779|C0886296
Results: At a median follow up of 11 years there was a 13% reduction in colorectal cancer mortality (95% confidence interval 3–22%) in the intervention group despite an uptake at first invitation of only approximately 50%.,Results: At median follow 11 13% reduction colorectal cancer mortality (95% confidence interval 3–22%) intervention uptake invitation 50%.,C1274040|G0000000|C0549183|C0332283|C0450371|C0450371|C0301630|C0555952|C0006826|C0026565|C0450371|C0237529|C1272706|G0000000|C0886296|C0243144|C2826348|C0450371
"At 18 months of age, anthropometric assessments revealed no significant differences in the children’s mean length, mean weight, the prevalence of stunting, or head or mid-upper arm circumference between the intervention groups for all participants in the iLiNS project [22].","At 18 months age, anthropometric assessments revealed differences children’s length, weight, prevalence stunting, head mid-upper arm circumference intervention participants iLiNS project [22].",G0000000|C0450371|C0439231|C0001779|C0003188|C1261322|C0443289|C1705241|G0000000|C1444754|C0005910|C0033105|C0018273|C0018670|C0444598|C0446516|C0332520|C0886296|C0679646|G0000000|C1709701|C0450371
"Clinical Outcomes: Bleeding Events and Platelet Transfusions in the 26-Week Test Treatment Period Abbreviations: CI, confidence interval; CSBE, clinically significant bleeding events; CTCAE, Common Terminology Criteria for Adverse Events; HR, hazard ratio; pt-yrs, patient-years; RR, relative risk (used as the Poisson regression model was applied because of the low event incidence).","Clinical Outcomes: Bleeding Events Platelet Transfusions 26-Week Test Treatment Period Abbreviations: CI, confidence interval; CSBE, clinically bleeding events; CTCAE, Common Terminology Criteria Adverse Events; HR, hazard ratio; pt-yrs, patient-years; RR, relative risk (used Poisson regression model applied low event incidence).",C0205210|C1274040|C0019080|C0441471|C0005821|C0005841|C0450371|C0022885|C0039798|C0439531|C0000723|C0008107|C0237529|C1272706|G0000000|G0000000|C0019080|C0441471|C1516728|C0205214|C0028275|C0243161|G0000000|C0441471|G0000000|C0598697|C0456603|C0699718|C0030705|G0000000|C0080103|C0035647|C1273517|G0000000|C0684320|C3161035|C4048755|C0205251|C0441471|C0021149
"Secondary outcomes are self-perceived burden from informal care (EDIZ), patient experienced continuity of medical care (NCQ), patient and caregiver satisfaction with the teleconsultation (PSQ), the experienced problems and needs in palliative care (PNPC-sv) and the number of hospital admissions.","Secondary outcomes self-perceived burden informal care (EDIZ), patient experienced continuity medical care (NCQ), patient caregiver satisfaction teleconsultation (PSQ), experienced palliative care (PNPC-sv) hospital admissions.",C0027627|C1274040|C0036588|C2828008|G0000000|C1947933|G0000000|C0030705|C0237607|C0595960|C0199168|C1947933|G0000000|C0030705|C0085537|C0242428|C0282675|G0000000|C0237607|C0587605|C1947933|C0048592|C0019994|C0184666
The response rate was 48.7%.,The response rate 48.7%.,G0000000|C0871261|C0871208|C0450371
"A secondary end point was OS, which was defined as time from registration to death as a result of any cause.","A secondary OS, defined time registration death result cause.",G0000000|C0027627|C0229090|C1704788|C0040223|C1514821|C0011065|C1274040|C0015127
The primary end point was overall survival (OS).,The primary survival (OS).,G0000000|C0205225|C0038952|C0229090
"There was also no difference in the time interval between procedure and delivery in women who had a cesarean for arrest and those who did not require cesarean for arrest (25.7 months vs. 33.0 months, p=0.82).","There difference time interval procedure delivery women cesarean arrest require cesarean arrest (25.7 months vs. 33.0 months, p=0.82).",G0000000|C1705241|C0040223|C1272706|C0184661|C0011209|C0043210|C3841297|C0237477|G0000000|C3841297|C0237477|C0450371|C0439231|G0000000|C0450371|C0439231|C0369773
The clinical outcomes of the 7 subjects who belonged to cluster III at the start of treatment were remission maintained in 2 of the 4 patients in the Bio-Three group and 2 of the 3 patients in the placebo group.,The clinical outcomes 7 subjects belonged cluster III start treatment remission maintained 2 4 patients Bio-Three 2 3 patients placebo group.,G0000000|C0205210|C1274040|G0000000|C0681850|G0000000|C1555715|C0439070|C0439659|C0039798|C0544452|C1314677|G0000000|G0000000|C0030705|C3844595|G0000000|G0000000|C0030705|C0032042|C0441833
"Secondary endpoints were clinical performance, health-related quality of life (HRQOL) and survival.","Secondary endpoints clinical performance, health-related quality life (HRQOL) survival.",C0027627|C2349179|C0205210|C0597198|C0018684|C0332306|C0376558|G0000000|C0038952
"Primary endpoint of the study was 12-month survival, secondary endpoints overall survival, time to progression and tumor response according to standard Response Evaluation Criteria In Solid Tumors (RECIST criteria) [13], toxicity according to ECOG criteria [14] and quality of life assessed by means of the FACT-Hep questionnaire [15] (Figure (Figure1).1).","Primary endpoint study 12-month survival, secondary endpoints survival, time progression tumor response standard Response Evaluation Criteria In Solid Tumors (RECIST criteria) [13], toxicity ECOG criteria [14] quality life assessed FACT-Hep questionnaire [15] (Figure (Figure1).1).",C0205225|C2349179|C0557651|C0450371|C0038952|C0027627|C2349179|C0038952|C0040223|C0242656|C0027651|C0871261|C1442989|C0871261|C0220825|C0243161|G0000000|C0205208|C0027651|C1709926|C0243161|C0450371|C0040539|C0430797|C0243161|C0450371|C0332306|C0376558|C1516048|C3641878|C0034394|C0450371|G0000000|G0000000
"Primary outcomes were pain, anxiety, and alertness; secondary outcomes were quality of life and sleep.","Primary outcomes pain, anxiety, alertness; secondary outcomes quality life sleep.",C0205225|C1274040|C0030193|C0003467|C1443086|C0027627|C1274040|C0332306|C0376558|C0037313
The primary endpoint was the incidence of biopsy-proven prostate cancer over the course of the study.,The primary endpoint incidence biopsy-proven prostate cancer study.,G0000000|C0205225|C2349179|C0021149|C0005558|C0033572|C0006826|C0557651
"Other outcomes of interest such as tender point sensitivity, health-related quality of life (HRQOL), sleep quality, and physician's global assessment were also measured at each assessment.","Other outcomes tender sensitivity, health-related quality life (HRQOL), sleep quality, physician's global assessment measured assessment.",G0000000|C1274040|C0234234|C0020517|C0018684|C0332306|C0376558|G0000000|C0037313|C0332306|C0031831|C0205246|C1261322|C0444706|C1261322
"We will compare the outcome variables (SDS, SAS, MAAS, Quality of Life Index, and MMAS) between the two groups using the χ2 test for categorical variables and Student t or Wilcoxon tests for continuous variables.","We compare outcome variables (SDS, SAS, MAAS, Quality Life Index, MMAS) χ2 test categorical variables Student Wilcoxon tests continuous variables.",G0000000|C1707455|C1274040|C0439828|C3813719|C0605290|C1416953|C0332306|C0376558|C0918012|G0000000|G0000000|C0022885|C0683312|C0439828|C0038492|G0000000|C0022885|C0549178|C0439828
Both groups were followed for progression-free survival (PFS) and overall survival (OS).,Both progression-free survival (PFS) survival (OS).,G0000000|C0242656|C0038952|C0242792|C0038952|C0229090
"Criteria for efficacy assessment were response rate, progression-free survival and overall survival.","Criteria efficacy assessment response rate, progression-free survival survival.",C0243161|C1280519|C1261322|C0871261|C0871208|C0242656|C0038952|C0038952
"Secondary aims assess patient quality of life, symptom distress, unmet supportive care needs, preparation for treatment, psychosexual functioning and vaginal stenosis.","Secondary aims assess patient quality life, symptom distress, unmet supportive care needs, preparation treatment, psychosexual functioning vaginal stenosis.",C0027627|C1947946|C1516048|C0030705|C0332306|C0376558|C1457887|C0231303|C3274904|C1521721|C1947933|C0027552|C1521827|C0039798|G0000000|C0205245|C0042232|C0678234
We measured depressive symptoms using a 15-item modified version of Radloff's (1977) original 20-item Center for Epidemiological Studies Depression Scale (CES-D).,We measured depressive symptoms 15-item modified version Radloff's (1977) original 20-item Center Epidemiological Studies Depression Scale (CES-D).,G0000000|C0444706|G0000000|C0683368|C0450371|C0392747|C0333052|G0000000|G0000000|C0205313|C0450371|C0205099|C0014507|C0947630|C0011570|C0175659|C2699160
"The gabapentin group, but not the placebo group, showed significant reductions from baseline to the end of treatment on the Marijuana Problems Scale total score (gabapentin change score=3.4, 95% CI 0.8–6.0, p=0.02).","The gabapentin group, placebo group, reductions baseline treatment Marijuana Problems Scale total score (gabapentin change score=3.4, 95% CI 0.8–6.0, p=0.02).",G0000000|C0060926|C0441833|C0032042|C0441833|C0301630|C0168634|C0039798|C0024808|C1546466|C0175659|C0439175|C0449820|C0060926|C0392747|C0449820|C0450371|C0008107|G0000000|C0369773
"Body weight did not change in either group, but there was a modest but statistically significant reduction in mean total body water in the intervention group (0.50 L, p<0.01) compared with no change in the control group (0.26 L, not statistically significant.).","Body weight change group, modest statistically reduction total body water intervention (0.50 L, p<0.01) compared change control (0.26 L, statistically significant.).",C0242821|C0005910|C0392747|C0441833|C4054480|C0038215|C0301630|C0439175|C0242821|C0043047|C0886296|G0000000|C0369773|C1707455|C0392747|C0243148|G0000000|C0038215|C0237881
"We also found no association between 5 commonly used mineral supplements (calcium, iron, magnesium, zinc, or selenium) and UC (HR for Ca >=319 mg/day vs. non-use 1.00 CI 0.71,1.40, p-trend=0.66; HR for Se >=20 mcg/day vs. non-use 0.97 CI 0.72,1.31, p-trend=0.740) (data not shown).","We association 5 commonly mineral supplements (calcium, iron, magnesium, zinc, selenium) UC (HR Ca >=319 mg/day vs. non-use 1.00 CI 0.71,1.40, p-trend=0.66; HR Se >=20 mcg/day vs. non-use 0.97 CI 0.72,1.31, p-trend=0.740) (data shown).",G0000000|C0004083|G0000000|G0000000|C0006660|C0242295|C0006675|C0302583|C0024467|C0043481|C0036581|G0000000|G0000000|C3887642|C1442061|C0439422|G0000000|C1518422|C0450371|C0008107|C0450371|C0369773|G0000000|C0036919|C0450371|C0439426|G0000000|C1518422|C0450371|C0008107|C0450371|C0369773|C1511726|C1547282
"The two often cited primary endpoints, the number of bowel movements and fecal incontinence, were similar between the groups.","The cited primary endpoints, bowel movements fecal incontinence, groups.",G0000000|G0000000|C0205225|C2349179|C0021853|C0026649|C0015733|C0021167|C0441833
There was no evidence of any significant heterogeneity in treatment effect according to the baseline characteristics (data not shown).,There evidence heterogeneity treatment baseline characteristics (data shown).,G0000000|C3887511|C0019409|C0039798|C0168634|C1521970|C1511726|C1547282
"Safety endpoints included adverse events, clinical laboratory tests, electrocardiography, vital signs, physical examination, peripheral edema, and CV symptoms including events adjudicated by an independent Clinical Events Committee (CEC).","Safety endpoints included adverse events, clinical laboratory tests, electrocardiography, vital signs, physical examination, peripheral edema, CV symptoms including events adjudicated independent Clinical Events Committee (CEC).",C0036043|C2349179|C0332257|G0000000|C0441471|C0205210|C0022877|C0022885|C0013798|C0442732|C0220912|C0031809|G0000000|C0205100|C0013604|C3538987|C0683368|C0332257|C0441471|G0000000|C0085862|C0205210|C0441471|C2699414|C0279934
"With respect to secondary endpoints, efficacy endpoints OS and TTF will be evaluated according to the method of analysis of the primary endpoint.","With respect secondary endpoints, efficacy endpoints OS TTF evaluated method analysis primary endpoint.",G0000000|C0679133|C0027627|C2349179|C1280519|C2349179|C0229090|C1332112|C0220825|C0025663|C0002778|C0205225|C2349179
QOL of patients with breast cancer was measured by the Standard Instrument of Quality of Life Breast Cancer Survivors which belongs to the National Medical Center and Beckman Research Institute.,QOL patients breast cancer measured Standard Instrument Quality Life Breast Cancer Survivors belongs National Medical Center Beckman Research Institute.,C0518214|C0030705|C0006141|C0006826|C0444706|C1442989|C0348000|C0332306|C0376558|C0006141|C0006826|C0206194|G0000000|C3245503|C0199168|C0205099|G0000000|C0035168|C0021622
The primary outcome measure of the trial was maternal BP at 36 wk of gestation.,The primary outcome measure trial maternal BP 36 wk gestation.,G0000000|C0205225|C1274040|C0079809|C0008976|C2347083|C0037623|C0450371|C0332174|C0032961
"Additional end points included pregnancy within 5 years, assessed annually, and ovarian dysfunction, defined as amenorrhea for the preceding 3 months and FSH, estradiol, or inhibin B levels in the postmenopausal range, assessed at both year 1 and year 2.","Additional included pregnancy 5 years, assessed annually, ovarian dysfunction, defined amenorrhea preceding 3 months FSH, estradiol, inhibin B levels postmenopausal range, assessed 1 2.",C1524062|C0332257|C0032961|G0000000|C0439234|C1516048|C0332181|C0205065|C0031847|C1704788|C0002453|C0332152|G0000000|C0439231|G0000000|C0014912|C0021463|G0000000|C0441889|C0232970|C1514721|C1516048|G0000000|G0000000
The reductions in Hb levels in the TXA group were significantly smaller than the control group at both one day and one week post-operation (Fig.,The reductions Hb levels TXA control day week post-operation (Fig.,G0000000|C0301630|C0019046|C0441889|G0000000|C0243148|C0332173|C0332174|C0032790|C0349966
Secondary outcomes will be changes in parental efficacy in protecting children’s oral health and changes in children’s dental behaviors (outcome variables described in Table 2).,Secondary outcomes parental efficacy protecting children’s oral health children’s dental behaviors (outcome variables Table 2).,C0027627|C1274040|C0030551|C1280519|G0000000|G0000000|C0442027|C0018684|G0000000|C0011365|C0004927|C1274040|C0439828|C0039224|G0000000
"Secondary endpoints included time to exacerbation based on adherence recorded by the I-neb, P. aeruginosa bacterial density, quality of life, and safety parameters.","Secondary endpoints included time exacerbation based adherence recorded I-neb, P. aeruginosa bacterial density, quality life, safety parameters.",C0027627|C2349179|C0332257|C0040223|G0000000|C1527178|C1510802|C0034869|C0021966|C0369773|G0000000|C0521009|C0178587|C0332306|C0376558|C0036043|C0449381
"The histologic response was assessed according to the following categories: CR was defined as a complete reversal of premalignancy to normal epithelium with no new lesions, PR was defined as an improvement in degree of maturation of epithelium with no new lesions and no progression of any lesion, SD was defined as no change in histology and no appearance of new lesions or progression of any lesion.","The histologic response assessed categories: CR defined complete reversal premalignancy normal epithelium lesions, PR defined improvement degree maturation epithelium lesions progression lesion, SD defined change histology appearance lesions progression lesion.",G0000000|C0205462|C0871261|C1516048|C0683312|C0201975|C1704788|C0205197|C0443290|C0032927|C0205307|C0014609|C0221198|C0279759|C1704788|C2986411|C0441889|C0678723|C0014609|C0221198|C0242656|C0221198|C2699239|C1704788|C0392747|C0019638|C0233426|C0221198|C0242656|C0221198
"Secondary outcomes were calculated from daily diary card data during run-in and 4 weeks prior to each clinic visit or telephone contact and from two questionnaires: the Asthma Control Questionnaire (ACQ-5,20,21 all clinic visits) and the Satisfaction with Asthma Treatment Questionnaire (SATQ, after 1 and 12 months of treatment).22 Patients recorded daily the best of three morning and evening peak expiratory flow (PEF) values, asthma symptoms during night and day (3-point scale where 0=no symptoms and 3=incapacitating symptoms), nights with awakenings due to asthma symptoms, total number of budesonide/formoterol inhalations (SMART group), and intake of maintenance and as-needed medication (UC group).","Secondary outcomes calculated daily diary card data run-in 4 weeks prior clinic visit telephone contact questionnaires: Asthma Control Questionnaire (ACQ-5,20,21 clinic visits) Satisfaction Asthma Treatment Questionnaire (SATQ, 1 12 months treatment).22 Patients recorded daily morning evening peak expiratory flow (PEF) values, asthma symptoms night day (3-point scale 0=no symptoms 3=incapacitating symptoms), nights awakenings asthma symptoms, total budesonide/formoterol inhalations (SMART group), intake maintenance as-needed medication (UC group).",C0027627|C1274040|C0444686|C0332173|C0376660|C3275277|C1511726|C3274438|G0000000|C0439230|C0332152|C0002424|C0545082|C0039457|C0332158|C0034394|C0004096|C0243148|C0034394|C2919686|C0002424|C0545082|C0242428|C0004096|C0039798|C0034394|G0000000|G0000000|C0450371|C0439231|C0039798|C0030705|C0034869|C0332173|C0332170|C0587117|C0444505|C0231800|C0806140|C0030771|C0042295|C0004096|C0683368|C0240526|C0332173|C1552961|C0175659|G0000000|C0683368|G0000000|C0683368|C0240526|C1720052|C0004096|C0683368|C0439175|C1276807|C0004048|G0000000|C0441833|C1512806|C0024501|C1879745|C0013227|G0000000|C0441833
"Secondary outcome measures were change in clinical score, oximetry, number of bronchodilator treatments required before discharge (if not hospitalised) and need for systemic corticosteroids.","Secondary outcome measures change clinical score, oximetry, bronchodilator treatments required discharge (if hospitalised) systemic corticosteroids.",C0027627|C1274040|C0079809|C0392747|C0205210|C0449820|C0523807|C0006280|C0087111|C1514873|C0012621|G0000000|G0000000|C0205373|C0001617
"The primary end point was the 12-month, relapse-free survival rate.","The primary 12-month, relapse-free survival rate.",G0000000|C0205225|C0450371|C0035020|C0038952|C0871208
The primary endpoint is overall survival.,The primary endpoint survival.,G0000000|C0205225|C2349179|C0038952
"Secondary endpoints included: frequency of SREs, change in serum BSAP and change in self-reported pain.","Secondary endpoints included: frequency SREs, change serum BSAP change self-reported pain.",C0027627|C2349179|C0332257|C0376249|G0000000|C0392747|C0229671|C0312399|C0392747|C0681906|C0030193
Primary outcome criterion was the change in the Bronchitis Severity Score (BSS) from day 0 to day 7.,Primary outcome criterion change Bronchitis Severity Score (BSS) day 0 day 7.,C0205225|C1274040|C0243161|C0392747|C0006277|C0439793|C0449820|G0000000|C0332173|G0000000|C0332173|G0000000
"The measured outcomes of newborns were macrosomia, newborns’ weight, length and head circumference, apgar score, and newborns’ hyperbilirubinemia, hospitalization and hypoglycemia.","The measured outcomes newborns macrosomia, newborns’ weight, length head circumference, apgar score, newborns’ hyperbilirubinemia, hospitalization hypoglycemia.",G0000000|C0444706|C1274040|C0021289|C0158915|G0000000|C0005910|C1444754|C0018670|C0332520|C0741195|C0449820|G0000000|C0020433|C0019993|C0020615
"Secondary outcomes are functional impairments, psychological distress and quality of life.","Secondary outcomes functional impairments, psychological distress quality life.",C0027627|C1274040|C0205245|C0684336|C0205486|C0231303|C0332306|C0376558
"A dietary intervention (the FRD rich in fruits, vegetables, whole grains, and omega-3 fatty acid-rich foods) delivered via brief phone counseling sessions significantly decreased fatigue and improved sleep quality over the course of 3 months compared to an attention control in persistently fatigued breast cancer survivors.","A dietary intervention (the FRD rich fruits, vegetables, grains, omega-3 fatty acid-rich foods) delivered phone counseling sessions decreased fatigue improved sleep quality 3 months compared attention control persistently fatigued breast cancer survivors.",G0000000|C0012155|C0886296|G0000000|G0000000|C0699759|C0016767|C0042440|C0086369|C1719844|G0000000|C0001128|C0016452|C1705822|C1515258|C0010210|C1883016|C0205216|C0015672|C0184511|C0037313|C0332306|G0000000|C0439231|C1707455|C0004268|C0243148|C0750508|C0015672|C0006141|C0006826|C0206194
"The rates of neutrophil and platelet engraftment, graft failure, acute GVHD, chronic GVHD, death in the absence of relapse, and relapse were compared between the two groups with the use of a stratified log-rank test that treated relapse as a competing event for death in the absence of relapse and treated death as a competing risk for all other end points.","The rates neutrophil platelet engraftment, graft failure, acute GVHD, chronic GVHD, death absence relapse, relapse compared stratified log-rank test treated relapse competing event death absence relapse treated death competing risk points.",G0000000|C0871208|C0027950|C0005821|C0301944|C0181074|C0231174|C0205178|G0000000|C0205191|G0000000|C0011065|C0332197|C0035020|C0035020|C1707455|C0205363|C1708728|C0022885|C1522326|C0035020|G0000000|C0441471|C0011065|C0332197|C0035020|C1522326|C0011065|G0000000|C0035647|C1552961
"Between-arm differences were seen in favor of girls who received intervention on the quality of their communications with their mothers, F(1,541), p < .05, perceptions of family rules against their substance use, F(1,540), p < .0001, perceptions of their parents' monitoring of their extracurricular activities, whereabouts, and friends, F(1,541), p < .01, and normative beliefs about peer substance use, F(1,540), p < .001 (Table 2).","Between-arm differences favor girls received intervention quality communications mothers, F(1,541), < .05, perceptions family rules substance use, F(1,540), < .0001, perceptions parents' monitoring extracurricular activities, whereabouts, friends, F(1,541), < .01, normative beliefs peer substance use, F(1,540), < .001 (Table 2).",C0446516|C1705241|C0309049|C0870604|C1514756|C0886296|C0332306|C0009452|C0026591|C0016327|G0000000|C0450371|C0030971|C0015576|C0870077|C0439861|C0042153|C0016327|G0000000|G0000000|C0030971|C0030551|C0150369|G0000000|C0441655|G0000000|C0079382|C0016327|G0000000|C0450371|G0000000|C0004951|C0679739|C0439861|C0042153|C0016327|G0000000|C1442061|C0039224|G0000000
"Overall, the incidence of serious adverse events (SAE) was similar between all groups.","Overall, incidence adverse events (SAE) groups.",C0282416|C0021149|G0000000|C0441471|C1519255|C0441833
"Because the ovarian cancer patients had no measurable disease at study entry, the primary efficacy endpoint was progression-free survival (PFS).","Because ovarian cancer patients measurable disease study entry, primary efficacy endpoint progression-free survival (PFS).",G0000000|C0205065|C0006826|C0030705|C1513040|C0012634|C0557651|C1705654|C0205225|C1280519|C2349179|C0242656|C0038952|C0242792
"Secondary end points: progression-free survival (PFS), overall response rate (ORR), and safety.","Secondary points: progression-free survival (PFS), response rate (ORR), safety.",C0027627|C1552961|C0242656|C0038952|C0242792|C0871261|C0871208|G0000000|C0036043
"In conclusion, tremelimumab induces a low-frequency but reproducible durable response rate in patients with metastatic melanoma.","In conclusion, tremelimumab induces low-frequency reproducible durable response rate patients metastatic melanoma.",G0000000|C1707478|C2351038|C0205263|C0205213|C1514863|G0000000|C0871261|C0871208|C0030705|C0036525|C0025202
"More specifically, this trial aims to assess the effectiveness of the intervention on: (1) FC outcomes: distress (primary outcome), anxiety, depression, quality of life (QoL), needs, burden, perception of health, preparedness in caregiving, social support, care satisfaction, (2) Patient outcomes: distress, anxiety, depression, QoL, pain/other symptom relief, (3) Care process outcomes: FC and patient utilization of services.","More specifically, trial aims assess effectiveness intervention on: (1) FC outcomes: distress (primary outcome), anxiety, depression, quality life (QoL), needs, burden, perception health, preparedness caregiving, social support, care satisfaction, (2) Patient outcomes: distress, anxiety, depression, QoL, pain/other symptom relief, (3) Care process outcomes: FC patient utilization services.",C0205172|G0000000|C0008976|C1947946|C1516048|C1280519|C0886296|G0000000|G0000000|C2983605|C1274040|C0231303|C0205225|C1274040|C0003467|C0011570|C0332306|C0376558|C0518214|C0027552|C2828008|C0030971|C0018684|C1318963|G0000000|C0728831|C0183683|C1947933|C0242428|G0000000|C0030705|C1274040|C0231303|C0003467|C0011570|C0518214|C0030193|C1457887|C0564405|G0000000|C1947933|C1184743|C1274040|C2983605|C0030705|C0042153|C0557854
"Similarly, asthenopia grading was significantly decreased after wearing glasses for 12mo in the test group compared with the control group (P=0.013).","Similarly, asthenopia grading decreased wearing glasses 12mo test compared control (P=0.013).",G0000000|C0004095|C0441800|C0205216|G0000000|C0015421|G0000000|C0022885|C1707455|C0243148|C0369773
The primary outcome is the change in FAST (self-rated) and SOFAS (observer-rated) score pre-intervention to post intervention (e.g.,The primary outcome change FAST (self-rated) SOFAS (observer-rated) score pre-intervention post intervention (e.g.,G0000000|C0205225|C1274040|C0392747|C0015663|C0036588|G0000000|C0870992|C0449820|C2347663|C0687676|C0886296|G0000000
"The final results showed that adding docetaxel to the CF regimen (DCF) improved overall survival, response rate, time to disease progression and health-related quality of life, but was associated with a marked increase in haematological toxicity.","The final adding docetaxel CF regimen (DCF) improved survival, response rate, time disease progression health-related quality life, marked increase haematological toxicity.",G0000000|C0205088|C1883712|C0246415|C0009738|C0040808|C0030896|C0184511|C0038952|C0871261|C0871208|C0040223|C0012634|C0242656|C0018684|C0332306|C0376558|C0522501|C0442805|C0018943|C0040539
"Secondary outcomes include health related quality of life for patients at 24 weeks, carer health related quality of life at 12 and 24 weeks, patient and carer mood at 12 and 24 weeks, overall survival and analysis of healthcare utilisation and cost.","Secondary outcomes health quality life patients 24 weeks, carer health quality life 12 24 weeks, patient carer mood 12 24 weeks, survival analysis healthcare utilisation cost.",C0027627|C1274040|C0018684|C0332306|C0376558|C0030705|C0450371|C0439230|C0085537|C0018684|C0332306|C0376558|C0450371|C0450371|C0439230|C0030705|C0085537|C0026516|C0450371|C0450371|C0439230|C0038952|C0002778|C0086388|C0042153|C0010186
"While baseline levels of fasting blood glucose, cholesterol, and triglycerides did not vary between the groups following treatment, 4-wk blood cholesterol levels in the ICO group decreased significantly as compared with the GLU group (Table 4).","While baseline levels fasting blood glucose, cholesterol, triglycerides vary treatment, 4-wk blood cholesterol levels ICO decreased compared GLU (Table 4).",G0000000|C0168634|C0441889|C0015663|C0005767|C0017725|C0008377|C0041004|G0000000|C0039798|C0332174|C0005767|C0008377|C0441889|G0000000|C0205216|C1707455|C0061472|C0039224|G0000000
"While no significant treatment effect for pain severity was found, the SLCBT groups showed significantly greater improvements compared to controls on process measures of parental solicitousness, pain beliefs and catastrophizing, and additional outcomes of parent-reported functional disability, pain behaviors, child healthcare visits for abdominal pain, and (remote condition only) quality of life and missed school days.","While treatment pain severity found, SLCBT improvements compared controls process measures parental solicitousness, pain beliefs catastrophizing, additional outcomes parent-reported functional disability, pain behaviors, child healthcare visits abdominal pain, (remote condition only) quality life missed school days.",G0000000|C0039798|C0030193|C0439793|C0150312|G0000000|C2986411|C1707455|C0243148|C1184743|C0079809|C0030551|G0000000|C0030193|C0004951|C0563150|C1524062|C1274040|C4054215|C0205245|C0231170|C0030193|C0004927|C0008059|C0086388|C0545082|C0000726|C0030193|C0205157|C0012634|C0205171|C0332306|C0376558|C1705492|C0036375|C0439228
"Secondary endpoints included: Percentage of patients achieving the LDL-C goal of <2.59 mmol/L (100 mg/dL) at 12 weeks; percentage change in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) from baseline to 12 weeks.","Secondary endpoints included: Percentage patients achieving LDL-C goal <2.59 mmol/L (100 mg/dL) 12 weeks; percentage change total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) baseline 12 weeks.",C0027627|C2349179|C0332257|C0439165|C0030705|G0000000|G0000000|C0018017|C0450371|C1532563|C1442061|C0439269|C0450371|C0439230|C0439165|C0392747|C0439175|C0008377|C0039411|C0041004|C0337445|C0205250|C0023820|C0008377|C3715113|C0168634|C0450371|C0439230
"No program effects were found in the adolescents’ self-reported antisocial behavior, delinquency, or psychosocial functioning.","No program effects adolescents’ self-reported antisocial behavior, delinquency, psychosocial functioning.",G0000000|C1709697|C1280500|G0000000|C0681906|C0233523|C0004927|C0522174|C0542298|C0205245
"The gastrointestinal symptoms evaluated were diarrhea, nausea, vomiting, and lack of appetite; both their frequency and severity were assessed.","The gastrointestinal symptoms evaluated diarrhea, nausea, vomiting, lack appetite; frequency severity assessed.",G0000000|C0521362|C0683368|C0220825|C0011991|C0027497|C0042963|C0332268|C0003618|C0376249|C0439793|C1516048
Secondary end points were overall survival and cancer free survival.,Secondary survival cancer free survival.,C0027627|C0038952|C0006826|C0332296|C0038952
"Changes in the Quality of Life (QoL), Mood, Fatigue, Stress, and Cortisol Levels","Changes Quality Life (QoL), Mood, Fatigue, Stress, Cortisol Levels",C0392747|C0332306|C0376558|C0518214|C0026516|C0015672|C0038435|C0020268|C0441889
Adverse events were slightly more common in the budesonide pMDI group – although this was not thought to be clinically relevant – and the majority of patients who reported aggravated asthma as an adverse event were in this treatment group.,Adverse events common budesonide pMDI – clinically relevant – majority patients reported aggravated asthma adverse event treatment group.,G0000000|C0441471|C0205214|C0054201|G0000000|G0000000|G0000000|C2347946|G0000000|C0680220|C0030705|C0684224|C0436331|C0004096|G0000000|C0441471|C0039798|C0441833
"Perioperative anxiety symptoms will be assessed by the Hospital Anxiety and Depression Scale (HADS) at 1, 2, 3, 5, and 7 days after administration.","Perioperative anxiety symptoms assessed Hospital Anxiety Depression Scale (HADS) 1, 2, 3, 5, 7 days administration.",C1518988|C0003467|C0683368|C1516048|C0019994|C0003467|C0011570|C0175659|C0048008|G0000000|G0000000|G0000000|G0000000|G0000000|C0439228|C0001554
The present study showed a significant reverse association between green tea consumption and NPC.,The study reverse association green tea consumption NPC.,G0000000|C0557651|C1555029|C0004083|C0332583|C0039400|C0009830|G0000000
"Primary endpoints were the risks of treatment failure within 28 days, either unadjusted or adjusted by genotyping to distinguish recrudescence from new infection.","Primary endpoints risks treatment failure 28 days, unadjusted adjusted genotyping distinguish recrudescence infection.",C0205225|C2349179|C0035647|C0039798|C0231174|C0450371|C0439228|C1439367|C0456081|C1285573|G0000000|C0086898|C0009450
"The secondary endpoints were mortality and morbidity, including pancreatic fistula, intra-abdominal hemorrhage, and intra-abdominal abscess.","The secondary endpoints mortality morbidity, including pancreatic fistula, intra-abdominal hemorrhage, intra-abdominal abscess.",G0000000|C0027627|C2349179|C0026565|C0026538|C0332257|C0030274|C0016169|C0230168|C0019080|C0230168|C0000833
"This paper presents a practice-driven evaluation of a multi-layered community-based care package in Burundi, Indonesia, Sri Lanka and Sudan, through a set of indicators; (a) perceived treatment gains; (b) treatment satisfaction; (c) therapist burden; (d) access to care; (e) care package costs.","This paper practice-driven evaluation multi-layered community-based care package Burundi, Indonesia, Sri Lanka Sudan, set indicators; (a) perceived treatment gains; (b) treatment satisfaction; (c) therapist burden; (d) access care; (e) care package costs.",G0000000|C0030351|C0237607|C0220825|C0439064|C0009462|C1947933|C0013194|C0006448|C0021247|C1420401|C0445521|C0038642|C0036849|C0021212|G0000000|C0030971|C0039798|C1517378|G0000000|C0039798|C0242428|G0000000|C0871525|C2828008|C0073187|C0444454|C1947933|G0000000|C1947933|C0013194|C0010186
None of the baseline variables modified the effect of selenium on the primary endpoint.,None baseline variables modified selenium primary endpoint.,G0000000|C0168634|C0439828|C0392747|C0036581|C0205225|C2349179
"The major secondary end points included OS, overall RR (ORR), TTF, and safety.","The major secondary included OS, RR (ORR), TTF, safety.",G0000000|C0205082|C0027627|C0332257|C0229090|G0000000|G0000000|C1332112|C0036043
"In contrast, those in the delayed-intervention arm experienced no significant improvements in all of these measures from baseline to year 1, but did so from year 1 to year 2 (period of intervention exposure).","In contrast, delayed-intervention arm experienced improvements measures baseline 1, 1 2 (period intervention exposure).",G0000000|C0009924|C0205421|C0446516|C0237607|C2986411|C0079809|C0168634|G0000000|G0000000|G0000000|C0439531|C0886296|C0274281
"Secondary outcomes included measurement of 1) agreement between clinical diagnosis of septic shock with either the International Pediatric Sepsis Consensus Conference definition of septic shock (24) or ICD-10 diagnostic codes (25); 2) the number of eligible patients who were randomized within six hours from identification; 3) rate of protocol adherence (percentage of study drug doses correctly administered); 4) frequency of corticosteroid use outside of the protocol (pre-screening and post-randomization) and 5) differences between clinically important endpoints (PICU length of stay, hospital length of stay, time on vasopressors and duration of mechanical ventilation) between the two groups.","Secondary outcomes included measurement 1) agreement clinical diagnosis septic shock International Pediatric Sepsis Consensus Conference definition septic shock (24) ICD-10 diagnostic codes (25); 2) eligible patients randomized hours identification; 3) rate protocol adherence (percentage study drug doses correctly administered); 4) frequency corticosteroid protocol (pre-screening post-randomization) 5) differences clinically endpoints (PICU length stay, hospital length stay, time vasopressors duration mechanical ventilation) groups.",C0027627|C1274040|C0332257|C0242485|G0000000|C0680240|C0205210|C0011900|C0333534|C0036974|C1512888|C0030755|C0036690|C0376298|C0086047|C1550452|C0333534|C0036974|C0450371|C0021122|C0011900|C0919279|C0450371|G0000000|C1548635|C0030705|C0034656|C0439227|C0020792|G0000000|C0871208|C0442711|C1510802|C0439165|C0557651|C0013227|C0178602|G0000000|C1521801|G0000000|C0376249|C0001617|C0442711|C0332152|C0687676|G0000000|C1705241|G0000000|C2349179|C1046445|C1444754|G0000000|C0019994|C1444754|G0000000|C0040223|C0042397|C0449238|C0443254|C0035203|C0441833
There was no difference (p = 0.94) in local recurrence rates between study cohorts.,There difference (p = 0.94) local recurrence rates study cohorts.,G0000000|C1705241|C0369773|G0000000|C0450371|C0205276|C0034897|C0871208|C0557651|C0599755
"The primary study end point was pancreatic fistula or leakage, defined as amylase-rich fluid (amylase concentration >3 times the upper limit of normal serum amylase level) collected from the peripancreatic drains after postoperative day 3 with a drainage volume of >10 mL per day according to previous studies.8,15 Pancreatic leakage was further classified into clinical and subclinical leakage.5 Clinical leakage was defined as leakage in association with fever (>38°C), leukocytosis (white cell count >10 × 109/L), sepsis (evidence of infection and hemodynamic instability), need for percutaneous drainage for an amylase-rich fluid collection, or reoperation.","The primary study pancreatic fistula leakage, defined amylase-rich fluid (amylase concentration >3 times upper limit normal serum amylase level) collected peripancreatic drains postoperative day 3 drainage volume >10 mL day previous studies.8,15 Pancreatic leakage classified clinical subclinical leakage.5 Clinical leakage defined leakage association fever (>38°C), leukocytosis (white cell count >10 × 109/L), sepsis (evidence infection hemodynamic instability), percutaneous drainage amylase-rich fluid collection, reoperation.",G0000000|C0205225|C0557651|C0030274|C0016169|C0015376|C1704788|C0002712|C0005889|C0002712|C0004268|G0000000|C0040223|C1282910|C0439801|C0205307|C0229671|C0002712|C0441889|C1516695|C0442162|C0013103|C0032790|C0332173|G0000000|C0012621|C0449468|C0450371|C0439526|C0332173|C0205156|C0947630|C0030274|C0015376|C0008902|C0205210|C0205211|C0015376|C0205210|C0015376|C1704788|C0015376|C0004083|C0015967|G0000000|C0023518|C0007457|C0007634|C0750480|C0450371|G0000000|C1442061|C0036690|C3887511|C0009450|C0019010|C1444783|C0522523|C0012621|C0002712|C0005889|C1516698|C0035110
"Secondary endpoints included median progression-free survival (PFS), 12-month PFS, and safety.","Secondary endpoints included median progression-free survival (PFS), 12-month PFS, safety.",C0027627|C2349179|C0332257|C0549183|C0242656|C0038952|C0242792|C0450371|C0242792|C0036043
"The primary end point was median survival time and the secondary end points were response rate, median time to tumour progression and tolerance.","The primary median survival time secondary response rate, median time tumour progression tolerance.",G0000000|C0205225|C0549183|C0038952|C0040223|C0027627|C0871261|C0871208|C0549183|C0040223|C0027651|C0242656|C0013220
The primary endpoint was the ORR assessed by a central review committee in accordance with the Revised International Working Group criteria for malignant lymphoma.,The primary endpoint ORR assessed central review committee Revised International Working Group criteria malignant lymphoma.,G0000000|C0205225|C2349179|G0000000|C1516048|C0205099|C0282443|C2699414|C1527075|C1512888|C0043227|C0441833|C0243161|C0205282|C0024299
"Secondary endpoints included investigator (INV)-assessed PFS, ORR, and duration of response (DOR) per RECIST v1.1, overall survival (OS), patient-reported outcomes, and safety.","Secondary endpoints included investigator (INV)-assessed PFS, ORR, duration response (DOR) RECIST v1.1, survival (OS), patient-reported outcomes, safety.",C0027627|C2349179|C0332257|C0035173|C0021943|C0242792|G0000000|C0449238|C0871261|C0140057|C1709926|C0078433|C0038952|C0229090|C0747307|C1274040|C0036043
The findings indicate that yoga may have beneficial effects on QOL issues in women with stage I–III breast cancer during (neo)adjuvant cytotoxic and endocrine therapy.,The findings yoga beneficial effects QOL issues women stage I–III breast cancer (neo)adjuvant cytotoxic endocrine therapy.,G0000000|C2607943|C0043418|G0000000|C1280500|C0518214|C0033213|C0043210|C0205390|G0000000|C0006141|C0006826|C1366752|C0677881|C0014136|C0039798
"Dietary intake was assessed with four 24-hour telephone dietary recalls using the Nutrition Data System software (NDS-R 1994-2006; University of Minnesota, Minneapolis, MN), conducted on random days over a 3-week period, stratified for weekend and weekdays.","Dietary intake assessed 24-hour telephone dietary recalls Nutrition Data System software (NDS-R 1994-2006; University Minnesota, Minneapolis, MN), conducted random days 3-week period, stratified weekend weekdays.",C0012155|C1512806|C1516048|C0450371|C0039457|C0012155|C0034770|C0028707|C1511726|C0449913|C0037585|C0057753|G0000000|C0041740|C0026183|G0000000|C0026405|C0004927|C0034656|C0439228|C0332174|C0439531|C0205363|C0680190|C0680189
The intervention does not appear to have had a positive longer‐term effect on fruit and vegetable consumption.,The intervention positive longer‐term fruit vegetable consumption.,G0000000|C0886296|C0439178|G0000000|C0016767|C0042440|C0009830
Primary and secondary efficacy endpoints: Kaplan-Meier estimates of time to progression and overall survival.,Primary secondary efficacy endpoints: Kaplan-Meier estimates time progression survival.,C0205225|C0027627|C1280519|C2349179|G0000000|C0750572|C0040223|C0242656|C0038952
"The results revealed intra-articular administration of TXA decreased not only blood loss, but also knee joint swelling after TKA.","The revealed intra-articular administration TXA decreased blood loss, knee joint swelling TKA.",G0000000|C0443289|C0442108|C0001554|G0000000|C0205216|C0005767|C1517945|C0022742|C0022417|C0013604|G0000000
